Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Operating Income (2016 - 2025)

Historic Operating Income for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to -$40.0 million.

  • Viridian Therapeutics, Inc.\DE's Operating Income rose 5206.88% to -$40.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$328.1 million, marking a year-over-year decrease of 1592.56%. This contributed to the annual value of -$299.0 million for FY2024, which is 1752.21% down from last year.
  • Viridian Therapeutics, Inc.\DE's Operating Income amounted to -$40.0 million in Q3 2025, which was up 5206.88% from -$106.8 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's Operating Income's 5-year high stood at -$14.1 million during Q3 2021, with a 5-year trough of -$106.8 million in Q2 2025.
  • Its 5-year average for Operating Income is -$53.1 million, with a median of -$51.2 million in 2023.
  • Data for Viridian Therapeutics, Inc.\DE's Operating Income shows a peak YoY increase of 6790.11% (in 2021) and a maximum YoY decrease of 18236.59% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Operating Income stood at -$29.1 million in 2021, then plummeted by 68.72% to -$49.1 million in 2022, then tumbled by 45.68% to -$71.5 million in 2023, then fell by 22.38% to -$87.5 million in 2024, then surged by 54.26% to -$40.0 million in 2025.
  • Its Operating Income was -$40.0 million in Q3 2025, compared to -$106.8 million in Q2 2025 and -$93.9 million in Q1 2025.